Novo Nordisk Reports New CagriSema Data At EASD 2026
Novo Nordisk announced new data on its investigational obesity and diabetes drug CagriSema, showing effects on food cravings, eating behavior, organ fat, and bone health. The data were presented at the European Association for the Study of Diabetes (EASD).